Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05935007 · ClinicalTrials.gov registry record

Aveir DR Real-World Evidence Post-Approval Study

A clinical trial of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.

Recruiting
Registry status
1,805
Enrollment target
1
Study location

NCT05935007 is a study of Bradycardia and Arrythmia that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 1,805 participants, below the 4,350-participant average among 29 other Bradycardia trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05935007, a study of Bradycardia and Arrythmia, is actively recruiting participants, sponsored by Abbott Medical Devices.

RECRUITING
Registry status
1,805 participants
Enrollment target
1
Study location

Study Summary

The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.

Interventions

  • DEVICE Aveir DR Leadless Pacemaker System

Study Locations (1)

California

  • Abbott - Sylmar

Trial Details

FieldValue
Enrollment Target 1,805 participants
Start Date 2023-10-31
Est. Completion 2030-01

Sponsor

Abbott Medical Devices

261 total trials

What the Registry Record Tells You About NCT05935007

The ClinicalTrials.gov registry entry for NCT05935007 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,805 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,350-participant average among 29 other Bradycardia trials with a reported enrollment target (59% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Aveir DR Leadless Pacemaker System is the first listed.

NCT05935007 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05935007 about?

NCT05935007 is a clinical study titled "Aveir DR Real-World Evidence Post-Approval Study". The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.

What is the current status of trial NCT05935007?

This trial is currently recruiting. The enrollment target is 1,805 participants. The study started on 2023-10-31. Estimated completion is 2030-01.

What conditions does trial NCT05935007 study?

This clinical trial studies the following conditions: Bradycardia, Arrythmia, Cardiac Pacemaker.

What interventions are being tested in trial NCT05935007?

The interventions under investigation include: Aveir DR Leadless Pacemaker System (DEVICE).

Who is sponsoring clinical trial NCT05935007?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05935007 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bradycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.